Journal of Clinical Virology
Volume 29, Issue 3 , Pages 152-159 , March 2004

Drug resistance in non-subtype B HIV-1

Received 28 January 2003 ,Accepted 4 April 2003.

References 

  1. Adje C, Cheingsong R, Roels TH, et al.  High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J. Acquir. Immune Defic. Syndr. 2001;26:501–506
  2. Balotta C, Facchi G, Violin M, et al.  Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J. Acquir. Immune Defic. Syndr. 2001;27:499–505
  3. Barlow KL, Tatt ID, Cane PA, Pillay D, Clewley JP. Recombinant strains of HIV type 1 in the United Kingdom. AIDS Res. Hum. Retroviruses. 2001;17:467–474
  4. Baxter JD, Mayers DL, Wentworth DN, et al.  A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000;14:F83–F93
  5. Boden D, Hurley A, Zhang L, et al.  HIV-1 drug resistance in newly infected individuals. J. Am. Med. Assoc. 1999;282:1135–1141
  6. Boni J, Pyra H, Gebhardt M, et al.  High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland. J. Acquir. Immune Defic. Syndr. 1999;22:174–179
  7. Brindeiro PA, Brindeiro RM, Mortensen C, et al.  Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy. J. Clin. Microbiol. 2002;40:4512–4519
  8. Brodine SK, Shaffer RA, Starkey MJ, et al.  Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann. Intern. Med. 1999;131:502–506
  9. Cane PA, de Ruiter A, Rice PA, Wiselka M, Fox R, Pillay D. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom. J. Clin. Microbiol. 2001;39:2652–2654
  10. Caride E, Brindeiro R, Hertogs K, et al.  Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. Virology. 2000;275:107–115
  11. Caride E, Hertogs K, Larder B, et al.  Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Genes. 2001;23:193–202
  12. Cingolani A, Antinori A, Rizzo MG, et al.  Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 2002;16:369–379
  13. Clavel F, Guetard D, Brun-Vezinet F, et al.  Isolation of a new human retrovirus from West African patients with AIDS. Science. 1986;233:343–346
  14. Clevenbergh P, Cua E, Dam E, et al.  Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naive HIV- infected patients. HIV Clin. Trials. 2002;3:36–44
  15. Cohen CJ, Hunt S, Sension M, et al.  A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579–588
  16. Couturier E, Damond F, Roques P, et al.  HIV-1 diversity in France, 1996–1998. The AC 11 laboratory network. AIDS. 2000;14:289–296
  17. De Cock KM, Adjorlolo G, Ekpini E, et al.  Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. J. Am. Med. Assoc. 1993;270:2083–2086
  18. Deeks SG. Nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. 2001;26(suppl. 1):S25–S33
  19. DeGruttola V, Dix L, D'Aquila R, et al.  The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther. 2000;5:41–48
  20. Deroo S, Robert I, Fontaine E, et al.  HIV-1 subtypes in Luxembourg, 1983–2000. AIDS. 2002;16:2461–2467
  21. Descamps D, Apetrei C, Collin G, Damond F, Simon F, Brun-Vezinet F. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors [letter]. AIDS. 1998;12:1109–1111
  22. Durant J, Clevenbergh P, Halfon P, et al.  Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999;353:2195–2199
  23. Erice A, Mayers DL, Strike DG, et al.  Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. New Engl. J. Med. 1993;328:1163–1165
  24. Erickson JW, Gulnik SV, Markowitz M. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS. 1999;13(Suppl. A):S189–S204
  25. Fauci AS, Desrosiers RC. Pathogenesis of HIV and SIV. In:  Coffin JM,  Hughes SH,  Varmus HE editor. Retroviruses. New York: Cold Spring Harbor Laboratory Press; 1997;p. 587–636
  26. Felsenstein J. phylip (Phylogeny Inference Package) Version 3.5. Seattle: University of Washington; 1993;
  27. Fonjungo PN, Dash BC, Mpoudi EN, et al.  Molecular screening for HIV-1 group N and simian immunodeficiency virus cpz-like virus infections in Cameroon [letter]. AIDS. 2000;14:750–752
  28. Frater AJ, Beardall A, Ariyoshi K, et al.  Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS. 2001;15:1493–1502
  29. Gao F, Vidal N, Li Y, et al.  Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation. AIDS Res. Hum. Retroviruses. 2001;17:675–688
  30. Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl. Acad. Sci. USA. 2001;98:13907–13912
  31. Goudsmit J, de RA, de RE, de BR. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J. Virol. 1997;71:4479–4484
  32. Grossman Z, Vardinon N, Chemtob D, et al.  Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS. 2001;15:1453–1460
  33. Gurtler LG, Hauser PH, Eberle J, et al.  A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J. Virol. 1994;68:1581–1585
  34. Hahn BH, Shaw GM, De Cock KM, Sharp PM. AIDS as a zoonosis: scientific and public health implications. Science. 2000;287:607–614
  35. Hanna GJ, D'Aquila RT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin. Infect. Dis. 2001;32:774–782
  36. Haubrich R, Demeter L. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. J. Acquir. Immune Defic. Syndr. 2001;26(suppl. 1):S51–S59
  37. Haubrich R, Keiser P, Kemper C, et al.  CCTG 575: a randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy. Antivir. Ther. 2001;6:63
  38. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society—USA Panel. J. Am. Med. Assoc. 2000;283:2417–2426
  39. Hizi A, Tal R, Shaharabany M, et al.  Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob. Agents Chemother. 1993;37:1037–1042
  40. Holguin A, Aracil B, Alvarez A, Barros C, Soriano V. Prevalence of human immunodeficiency virus type 1 (HIV-1) non-B subtypes in foreigners living in Madrid, Spain, and comparison of the performances of the AMPLICOR HIV-1 MONITOR version 1.0 and the new automated version 1.5. J. Clin. Microbiol. 2001;39:1850–1854
  41. Holguin A, Soriano V. Resistance to antiretroviral agents in individuals with HIV-1 non-B subtypes. HIV Clin. Trials. 2002;3:403–411
  42. Hu DJ, Dondero TJ, Rayfield MA, et al.  The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. J. Am. Med. Assoc. 1996;275:210–216
  43. Irwin KL, Pau CP, Lupo D, et al.  Presence of human immunodeficiency virus (HIV) type 1 subtype A infection in a New York community with high HIV prevalence: a sentinel site for monitoring HIV genetic diversity in North America. Centers for Disease Control and Prevention-Bronx Lebanon HIV Serosurvey Team. J. Infect. Dis. 1997;176:1629–1633
  44. Jaffe HW, Schochetman G. Group O human immunodeficiency virus-1 infections. Infect. Dis. Clin. North Am. 1998;12:39–46
  45. Janssens W, Heyndrickx L, Van der Auwera G, et al.  Interpatient genetic variability of HIV-1 group O. AIDS. 1999;13:41–48
  46. Kanki PJ, De Cock KM. Epidemiology and natural history of HIV-2. AIDS. 1994;8(Suppl. 1):S85–S93
  47. Kantor R, Machekano R, Gonzales MJ, Dupnik BS, Schapiro JM, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded model integrating natural language text and sequence analysis. Nucleic Acids Res. 2001;29:296–299
  48. Kantor R, Zijenah LS, Shafer RW, et al.  HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Res. Hum. Retroviruses. 2002;18:1407–1413
  49. Kantor R, Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev. 2003;5:25–35
  50. Kaplan AH, Michael SF, Wehbie RS, et al.  Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc. Natl. Acad. Sci. USA. 1994;91:5597–5601
  51. Korber B, Muldoon M, Theiler J, et al.  Timing the ancestor of the HIV-1 pandemic strains. Science. 2000;288:1789–1796
  52. Kuiken C, Foley B, Hahn B, et al.  HIV Sequence Compendium 2000. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 2000;
  53. Little SJ, Daar ES, D'Aquila RT, et al.  Reduced antiretroviral drug susceptibility among patients with primary HIV infection. J. Am. Med. Assoc. 1999;282:1142–1149
  54. Little SJ, Holte S, Routy JP, et al.  Antiretroviral-drug resistance among patients recently infected with HIV. New Engl. J. Med. 2002;347:385–394
  55. Loveday C. International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. 2001;26(suppl. 1):S10–S24
  56. Maguire M, Shortino D, Klein A, et al.  Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob. Agents Chemother. 2002;46:731–738
  57. McCutchan FE. Understanding the genetic diversity of HIV-1. AIDS. 2000;14:S31–S44
  58. Meynard JL, Vray M, Morand-Joubert L, et al.  Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 2002;16:727–736
  59. Miller V. Resistance to protease inhibitors. J. Acquir. Immune Defic. Syndr. 2001;26(suppl. 1):S34–S50
  60. Nkengasong J, Sylla-Koko F, Peeters M, et al.  HIV-1 group O virus infection in Abidjan, Cote d'Ivoire. AIDS. 1998;12:1565–1566
  61. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J. Acquir. Immune Defic. Syndr. 2002;29:184–190
  62. Peeters M. The genetic variability of HIV-1 and its implications. Transfus. Clin. Biol. 2001;8:222–225
  63. Peeters M, Sharp PM. Genetic diversity of HIV-1: the moving target. AIDS. 2000;14:S129–S140
  64. Perez-Alvarez L, Cuevas MT, Villahermosa ML, et al.  Prevalence of drug resistance mutations in B, non-B subtypes, and recombinant forms of human immunodeficiency virus type 1 in infected individuals in Spain (Galicia). J. Hum. Virol. 2001;4:35–38
  65. Perez-Alvarez L, Thomson MM, Villahermosa ML, et al.  HIV-1 subtype G and BG recombinant viruses in Spanish natives: evidence of characteristic mutations in reverse transcriptase and protease. AIDS. 2001;15:1907–1910
  66. Pillay D, Walker AS, Gibb DM, et al.  Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the paediatric European network for treatment of AIDS (PENTA) 5 Trial. J. Infect. Dis. 2002;186:617–625
  67. Reeves JD, Doms RW. Human immunodeficiency virus type 2. J. Gen. Virol. 2002;83:1253–1265
  68. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc. Natl. Acad. Sci. USA. 2002;99:14410–14415
  69. Richman D, Bozzette S, Morton S, et al. The prevalence of antiretroviral drug resistance in the US, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2001. p. Abstract LB-17.
  70. Robertson DL, Hahn BH, Sharp PM. Recombination in AIDS viruses. J. Mol. Evol. 1995;40:249–259
  71. Robertson DL, Sharp PM, McCutchan FE, Hahn BH. Recombination in HIV-1 [letter]. Nature. 1995;374:124–126
  72. Robertson DL, Anderson JL, Bradac JA, et al.  HIV-1 nomenclature proposal a reference guide to HIV-1 classification. In:  Kuiken CL,  Foley B,  Hahn BH, et al. editor. Human Retroviruses and AIDS: a Compilation and Analysis of Nucleic and Amino Acid Sequences. Los Alamos, NM: Los Alamos National Laboratory; 2000;p. 492–505
  73. Robertson DL, Anderson JP, Bradac JA, et al.  HIV-1 nomenclature proposal [letter]. Science. 2000;288:55–56
  74. Rubio A, Leal M, Pineda JA, et al.  Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1-infected antiviral-naive patients from 1989 to 1996. AIDS. 1997;11:1184–1186
  75. Ruibal-Brunet IJ, Cuevas MT, Diaz-Torres H, et al.  Genotypic resistance mutations to antiretroviral drugs in HIV-1 B and non-B subtypes from Cuba. Rev. Panam. Salud. Publica. 2001;10:174–180
  76. Salminen MO, Carr JK, Burke DS, McCutchan FE. Identification of breakpoints in intergenotypic recombinants of HIV type 1 by bootscanning. AIDS Res. Hum. Retroviruses. 1995;11:1423–1425
  77. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 2002;15:247–277
  78. Shafer RW, Kantor R, Gonzales MJ. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Rev. 2000;2:211–218
  79. Simon F, Mauclere P, Roques P, et al.  Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat. Med. 1998;4:1032–1037
  80. Soriano V, de Mendoza C. Genetic mechanisms of resistance to NRTI and NNRTI. HIV Clin. Trials. 2002;3:237–248
  81. Soriano V, de Mendoza C. Genetic mechanisms of resistance to protease inhibitors and entry inhibitors. HIV Clin. Trials. 2002;3:249–257
  82. Thomson MM, Najera R. Travel and the introduction of human immunodeficiency virus type 1 non- B subtype genetic forms into Western countries. Clin. Infect. Dis. 2001;32:1732–1737
  83. Triques K, Bourgeois A, Vidal N, et al.  Near-full-length genome sequencing of divergent African HIV type 1 subtype F viruses leads to the identification of a new HIV type 1 subtype designated K. AIDS Res. Hum. Retroviruses. 2000;16:139–151
  84. Tural C, Ruiz L, Holtzer C, et al.  Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002;16:209–218
  85. Vanden HM, Peeters M, Jannes G, et al.  Sequence analysis of a highly divergent HIV-1-related lentivirus isolated from a wild captured chimpanzee. Virology. 1996;221:346–350
  86. Vergne L, Malonga-Mouellet G, Mistoul I, et al.  Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J. Acquir. Immune Defic. Syndr. 2002;29:165–168
  87. Weidle PJ, Malamba S, Mwebaze R, et al.  Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients’ response, survival, and drug resistance. Lancet. 2002;360:34–40
  88. Yang G, Song Q, Charles M, Drosopoulos WC, Arnold E, Prasad VR. Use of chimeric human immunodeficiency virus types 1 and 2 reverse transcriptases for structure–function analysis and for mapping susceptibility to nonnucleoside inhibitors. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996;11:326–333
  89. Yerly S, Rakik A, De Loes SK, et al.  Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J. Virol. 1998;72:3520–3523
  90. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet. 1999;354:729–733

PII: S1386-6532(03)00115-X

doi: 10.1016/S1386-6532(03)00115-X

Journal of Clinical Virology
Volume 29, Issue 3 , Pages 152-159 , March 2004

Article Tools

* Image Usage & Resolution